Oral Carnitine in Heart Failure Patients
Recruiting · NCT07201714 · Interventional (participants receive a specific treatment)
View the official record on ClinicalTrials.gov →Interventions studied
Levocarnitine
What this trial is about
Heart failure is a condition in which the heart is unable to pump blood effectively, leading to symptoms like being more tired, shortness of breath, and swelling in the body. Carnitine is a naturally occurring substance in the body that plays a role in turning fat into energy. This study will determine whether oral L-Carnitine supplementation can improve symptoms, enhance heart function and possibly improve the quality of life in individuals with heart failure.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Early Phase 1
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Clinical-pathological diagnosis of heart failure with some degree of cardiorenal syndrome
- Stage 1, 2, 3a, 3b, or 4 chronic kidney disease
- Age ≥ 18 years
- Able to speak and read English
- Willing and able to provide consent
Exclusion criteria
- Estimated GFR \<15 mL/min/1.73m2 or Stage 5 chronic kidney disease
- Currently undergoing renal replacement therapy of any kind
- Pregnant, breastfeeding or intending pregnancy
- History of seizures of any type
- Known allergy to levocarnitine, magnesium stearate, microcrystalline cellulose or povidone
- Unable to provide consent
Where it is running
1 location listed.
- London Health Sciences Centre - London, Ontario, Canada